General Information
Version
10.0
Revision date
2025-04-14
Product name
Molnupiravir Capsule Formulation
1.2.1 Relevant identified uses
Pharmaceutical
Emergency telephone
+27 11 655 3000, +1-908-423-6000
Icons in SDS
Company Information
company name
MSD
e-mail address of the competent person responsible for the Safety Data Sheet
EHSDATASTEWARD@msd.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H372
Hazard statements
Code
Statements
H372
Causes damage to organs through prolonged or repeated exposure
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H372 Causes damage to organs through prolonged or re- peated exposure.
Prevention
P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product.
Response
P314 Get medical advice/ attention if you feel unwell.
Hazardous Ingredients
Molnupiravir
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. May form explosive dust-air mixture during processing, handling or other means. Dust contact with the eyes can lead to mechanical irritation.
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) Specific target organ toxicity - repeated H372: Causes damage to organs through pro- exposure, Category 1 longed or repeated exposure.
